Trial Profile
A Phase I Study to Evaluate the Safety/Tolerability and Pharmacokinetics of TOP1288 Rectal Single and Multiple Ascending Doses in Healthy Subjects and Multiple Doses in Subjects With Ulcerative Colitis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs TOP 1288 (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions; First in man
- Sponsors TopiVert
- 24 May 2016 Results study of single and multiple ascending doses in healthy volunteers (n=61) presented at the Digestive Disease Week 2016
- 10 May 2016 Planned primary completion date changed from 1 Jan 2016 to 1 Jul 2016.
- 09 May 2016 Results will be presented a the Digestive Disease Week (DDW) 2016, according to a TopiVert media release.